Literature DB >> 16283154

[Study activities for testicular cancer].

S Krege1.   

Abstract

Testicular cancer is one of the few tumors which are curable even at an advanced stage. This has been achieved both by the use of platinum based chemotherapy and by the interdisciplinary approach by urologists, internal oncologists and radio-oncologists. In 1988, the Interdisciplinary Testicular Cancer Study Group was founded. The aim of this group is to initiate clinical trials to improve the results in the treatment of this tumor. Furthermore, the group has published evidenced-based national and international guidelines for testicular cancer. This article gives an overview on the work of the group including current studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283154     DOI: 10.1007/s00120-005-0948-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  22 in total

1.  RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment.

Authors:  L Weissbach; R Bussar-Maatz; H Flechtner; U Pichlmeier; M Hartmann; L Keller
Journal:  Eur Urol       Date:  2000-05       Impact factor: 20.096

Review 2.  Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM).

Authors:  S Krege; R Souchon; H J Schmoll
Journal:  Eur Urol       Date:  2001-10       Impact factor: 20.096

3.  Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases.

Authors:  Klaus-Peter Dieckmann; Peter Albers; Johannes Classen; Maike De Wit; Uwe Pichlmeier; Oliver Rick; Ulrich Müllerleile; Markus Kuczyk
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

4.  Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.

Authors:  Carsten Bokemeyer; Craig R Nichols; Jean-P Droz; Hans-J Schmoll; Alan Horwich; Arthur Gerl; Sophie D Fossa; Jörg Beyer; Jörg Pont; Lothar Kanz; Lawrence Einhorn; Jörg T Hartmann
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

5.  High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables.

Authors:  J Beyer; A Kramar; R Mandanas; W Linkesch; A Greinix; J P Droz; J L Pico; A Diehl; C Bokemeyer; H J Schmoll; C R Nichols; L H Einhorn; W Siegert
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

6.  Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.

Authors:  A Heidenreich; I A Sesterhenn; F K Mostofi; J W Moul
Journal:  Cancer       Date:  1998-09-01       Impact factor: 6.860

7.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.

Authors:  R T D Oliver; M D Mason; G M Mead; H von der Maase; G J S Rustin; J K Joffe; R de Wit; N Aass; J D Graham; R Coleman; S J Kirk; S P Stenning
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

8.  Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors.

Authors:  J T Hartmann; C R Nichols; J-P Droz; A Horwich; A Gerl; S D Fossa; J Beyer; J Pont; L Kanz; L Einhorn; C Bokemeyer
Journal:  Ann Oncol       Date:  2002-07       Impact factor: 32.976

9.  Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group.

Authors:  Peter Albers; Lothar Weissbach; Susanne Krege; Sabine Kliesch; Michael Hartmann; Axel Heidenreich; Peter Walz; Markus Kuczyk; Rolf Fimmers
Journal:  J Urol       Date:  2004-05       Impact factor: 7.450

10.  High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.

Authors:  W Siegert; J Beyer; I Strohscheer; H Baurmann; H Oettle; J Zingsem; R Zimmermann; C Bokemeyer; H J Schmoll; D Huhn
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.